Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Development and Commercialization of Aza-Epoxy Guaiane Derivatives for Treatment of Renal Cancer, 76026-76027 [2015-30752]

Download as PDF 76026 Federal Register / Vol. 80, No. 234 / Monday, December 7, 2015 / Notices Dated: November 20, 2015. Melanie Ross, CDR, USPHS, Designated Federal Officer, Advisory Group on Prevention, Health Promotion, and Integrative and Public Health, Office of the Surgeon General. [FR Doc. 2015–30749 Filed 12–4–15; 8:45 am] BILLING CODE 4163–18–P 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: November 30, 2015. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2015–30719 Filed 12–4–15; 8:45 am] National Institutes of Health BILLING CODE 4140–01–P National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meetings DEPARTMENT OF HEALTH AND HUMAN SERVICES mstockstill on DSK4VPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Alcohol Abuse and Alcoholism Initial Review Group; Neuroscience Review Subcommittee (AA–4). Date: March 2, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: NIAAA, NIH, 5635 Fishers Lane, Terrace Level, Room 508, Rockville, MD 20852. Contact Person: Beata Buzas, Ph.D., Scientific Review Officer, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 5635 Fishers Lane, Room 2081, Rockville, MD 20852, 301–443–0800, bbuzas@mail.nih.gov. Name of Committee: National Institute on Alcohol Abuse and Alcoholism Initial Review Group; Biomedical Research Review Subcommittee (AA1). Date: March 8, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: NIAAA, NIH, 5635 Fishers Lane, Terrace Level, Room 508, Rockville, MD 20852. Contact Person: Philippe Marmillot, Ph.D., Scientific Review Officer, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 5635 Fishers Lane, Room 2017, Bethesda, MD 20892, 301–443–2861, marmillotp@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; VerDate Sep<11>2014 18:36 Dec 04, 2015 Jkt 238001 National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI P01 Meeting II. Date: February 2–3, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington DC/Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Shakeel Ahmad, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W122, Bethesda, MD 20892–9750, 240–276–6349, ahmads@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE I Review. Date: February 3–4, 2016. Time: 8:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Wlodek Lopaczynski, MD, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 Room 7W608, Bethesda, MD 20892–9750, 240–276–6458, lopacw@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Innovative Research in Cancer Nanotechnology (IRCN). Date: February 25, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892– 9750, 240–276–5856, nkhann3@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: November 30, 2015. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–30718 Filed 12–4–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health (NIH) Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Development and Commercialization of Aza-Epoxy Guaiane Derivatives for Treatment of Renal Cancer National Institutes of Health. Notice. AGENCY: ACTION: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to ElexiMed LLC, a company having a place of business at 5003 Green Mountain Circle, Suite 4, Columbia, MD 21044, USA, to practice the inventions embodied in the following patent applications. Intellectual Property—PCT Patent Application No. PCT/US2015/014601, entitled ‘‘Aza-Englerin Analogues— Novel Natural Product-Based NitrogenContaining Anti-Cancer Agents’’ filed February 5, 2015 (HHS Ref. No.: E–090– 2014/2–PCT–01); US Provisional Patent SUMMARY: E:\FR\FM\07DEN1.SGM 07DEN1 Federal Register / Vol. 80, No. 234 / Monday, December 7, 2015 / Notices Application No. 62/018,381, entitled ‘‘Aza-epoxy-guaiane derivatives and treatment of cancer’’ filed June 27, 2014 (HHS Ref. No. E–090–2014/1–US–01); and US Provisional Patent Application No. 61/936,285, entitled ‘‘Aza-englerin analogues and use in cancer therapy’’ filed February 5, 2014 (HHS Ref. No. E– 090–2014/0–US–01). The patent rights in these inventions have been assigned to the Government of the United States of America and the University of Hawaii. The territory of the prospective StartUp Exclusive Evaluation Option License Agreement may be worldwide, and the field of use may be limited to ‘‘Development and commercialization of aza-epoxy guaiane derivatives for treatment of renal cancer.’’ Upon the expiration or termination of the Start-up Exclusive Evaluation Option License Agreement, ElexiMed LLC will have the exclusive right to execute a Start-Up Exclusive Patent License Agreement which will supersede and replace the Start-up Exclusive Evaluation Option License Agreement, with no greater field of use and territory than granted in the Startup Exclusive Evaluation Option License Agreement. DATES: Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before December 22, 2015 will be considered. ADDRESSES: Requests for copies of the patent application(s), inquiries, comments, and other materials relating to the contemplated Start-Up Exclusive Evaluation Option License Agreement should be directed to: Rose Freel, Ph.D., Licensing and Patenting Manager, Technology Transfer Center, National Cancer Institute, Riverside 5, Suite 400, 8490 Progress Drive, Frederick, MD 21702; telephone: 301–624–1257; Facsimile: 301–631–3027; Email: rose.freel@nih.gov. A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published or issued by the United States Patent and Trademark Office or the World Intellectual Property Organization. This technology describes aza-englerins, synthetic analogues of the natural product Englerin A which displays potent and selective anti-cancer properties in several cancer cell lines. The aza-englerins were developed as novel cancer therapeutics and show significant bioavailability after oral administration in mice. mstockstill on DSK4VPTVN1PROD with NOTICES SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 18:36 Dec 04, 2015 Jkt 238001 The prospective Start-Up Exclusive Evaluation Option License Agreement is being considered under the small business initiative launched on October 1, 2011 and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective StartUp Exclusive Evaluation Option License Agreement and a subsequent Start-Up Exclusive Patent License Agreement may be granted unless the NCI receives written evidence and argument, within fifteen (15) days from the date of this published notice, that establishes that the grant of the contemplated Start-Up Exclusive Evaluation Option License Agreement would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7. Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the contemplated Start-Up Exclusive Evaluation Option License Agreement. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: December 2, 2015. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2015–30752 Filed 12–4–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council for Biomedical Imaging and Bioengineering. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 76027 discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council for Biomedical Imaging and Bioengineering, NACBIB, January, 2016. Date: January 21, 2016. Open: 8:30 a.m. to 12:00 p.m. Agenda: Report from the Institute Director, other Institute Staff and Scientific Presentations. Place: The William F. Bolger Center, Franklin Building, Classroom 1, 9600 Newbridge Drive, Potomac, MD 20854. Closed: 1:00 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: The William F. Bolger Center, Franklin Building, Classroom 1, 9600 Newbridge Drive, Potomac, MD 20854. Contact Person: David George, Ph.D., Acting Associate Director, Office of Research Administration, National Institute of Biomedical Imaging and Bioengineering, 6707 Democracy Boulevard, Room 920, Bethesda, MD 20892. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https://www. nibib1.nih.gov/about/NACBIB/NACBIB.htm, where an agenda and any additional information for the meeting will be posted when available. Dated: December 2, 2015. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–30750 Filed 12–4–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council on Aging. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other E:\FR\FM\07DEN1.SGM 07DEN1

Agencies

[Federal Register Volume 80, Number 234 (Monday, December 7, 2015)]
[Notices]
[Pages 76026-76027]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-30752]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health (NIH)


Prospective Grant of Start-Up Exclusive Evaluation Option License 
Agreement: Development and Commercialization of Aza-Epoxy Guaiane 
Derivatives for Treatment of Renal Cancer

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Cancer Institute (NCI), National Institutes 
of Health, Department of Health and Human Services, is contemplating 
the grant of a Start-Up Exclusive Evaluation Option License Agreement 
to ElexiMed LLC, a company having a place of business at 5003 Green 
Mountain Circle, Suite 4, Columbia, MD 21044, USA, to practice the 
inventions embodied in the following patent applications.
    Intellectual Property--PCT Patent Application No. PCT/US2015/
014601, entitled ``Aza-Englerin Analogues--Novel Natural Product-Based 
Nitrogen-Containing Anti-Cancer Agents'' filed February 5, 2015 (HHS 
Ref. No.: E-090-2014/2-PCT-01); US Provisional Patent

[[Page 76027]]

Application No. 62/018,381, entitled ``Aza-epoxy-guaiane derivatives 
and treatment of cancer'' filed June 27, 2014 (HHS Ref. No. E-090-2014/
1-US-01); and US Provisional Patent Application No. 61/936,285, 
entitled ``Aza-englerin analogues and use in cancer therapy'' filed 
February 5, 2014 (HHS Ref. No. E-090-2014/0-US-01).
    The patent rights in these inventions have been assigned to the 
Government of the United States of America and the University of 
Hawaii.
    The territory of the prospective Start-Up Exclusive Evaluation 
Option License Agreement may be worldwide, and the field of use may be 
limited to ``Development and commercialization of aza-epoxy guaiane 
derivatives for treatment of renal cancer.''
    Upon the expiration or termination of the Start-up Exclusive 
Evaluation Option License Agreement, ElexiMed LLC will have the 
exclusive right to execute a Start-Up Exclusive Patent License 
Agreement which will supersede and replace the Start-up Exclusive 
Evaluation Option License Agreement, with no greater field of use and 
territory than granted in the Start-up Exclusive Evaluation Option 
License Agreement.

DATES: Only written comments and/or applications for a license which 
are received by the NCI Technology Transfer Center on or before 
December 22, 2015 will be considered.

ADDRESSES: Requests for copies of the patent application(s), inquiries, 
comments, and other materials relating to the contemplated Start-Up 
Exclusive Evaluation Option License Agreement should be directed to: 
Rose Freel, Ph.D., Licensing and Patenting Manager, Technology Transfer 
Center, National Cancer Institute, Riverside 5, Suite 400, 8490 
Progress Drive, Frederick, MD 21702; telephone: 301-624-1257; 
Facsimile: 301-631-3027; Email: rose.freel@nih.gov. A signed 
confidentiality nondisclosure agreement will be required to receive 
copies of any patent applications that have not been published or 
issued by the United States Patent and Trademark Office or the World 
Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: This technology describes aza-englerins, 
synthetic analogues of the natural product Englerin A which displays 
potent and selective anti-cancer properties in several cancer cell 
lines. The aza-englerins were developed as novel cancer therapeutics 
and show significant bioavailability after oral administration in mice.
    The prospective Start-Up Exclusive Evaluation Option License 
Agreement is being considered under the small business initiative 
launched on October 1, 2011 and will comply with the terms and 
conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective 
Start-Up Exclusive Evaluation Option License Agreement and a subsequent 
Start-Up Exclusive Patent License Agreement may be granted unless the 
NCI receives written evidence and argument, within fifteen (15) days 
from the date of this published notice, that establishes that the grant 
of the contemplated Start-Up Exclusive Evaluation Option License 
Agreement would not be consistent with the requirements of 35 U.S.C. 
209 and 37 CFR part 404.7.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice will be treated as objections 
to the grant of the contemplated Start-Up Exclusive Evaluation Option 
License Agreement. Comments and objections submitted to this notice 
will not be made available for public inspection and, to the extent 
permitted by law, will not be released under the Freedom of Information 
Act, 5 U.S.C. 552.

    Dated: December 2, 2015.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2015-30752 Filed 12-4-15; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.